| Literature DB >> 36246968 |
Shazia Rafiq1, Hamayun Zafar2,3,4, Syed Amir Gillani5, Muhammad Sharif Waqas6, Sidrah Liaqat7, Amna Zia7, Yasir Rafiq8.
Abstract
Purpose: Cervical radiculopathy is disorder of cervical spinal nerve root affecting large number of population. Previously many studies are conducted to design suitable protocol for management of this disorder, but they lack in quality. The purpose of this study was to compare the effects of neural mobilization and cervical isometrics on health-related quality of life and deep flexors endurance in cervical radiculopathy.Entities:
Mesh:
Year: 2022 PMID: 36246968 PMCID: PMC9556173 DOI: 10.1155/2022/9385459
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1The figure for a parallel design.
Comparison of craniocervical flexion test and 8 domains of SF 36 within the experimental group.
| Variable | — | Interquartile range | Mean ranka | Chi-square ( | Post hoc analysis |
|
|
|---|---|---|---|---|---|---|---|
| Craniocervical flexion (mmHg) | Base line | 21 (20 to 24) | 1.07 | 78.28, | Pre and midtreatment | -5.56 | <0.017 |
| After 2nd week | 24 (24 to 26) | 2.10 | Mid and posttreatment | -5.15 | <0.017 | ||
| After 4th week | 26 (24 to 28) | 2.83 | Pre and posttreatment | -5.78 | <0.017 | ||
| Physical functioning–SF36 | Baseline | 35 (20 to 55) | 1.15 | 73.92, | Pre and midtreatment | -4.59 | <0.017 |
| After 2nd week | 57 (35 to 70) | 1.94 | Mid and posttreatment | -5.43 | <0.017 | ||
| After 4th week | 75 (60 to 85) | 2.91 | Pre and posttreatment | -5.46 | <0.017 | ||
| Role limitation due to physical health–SF36 | Baseline | 0 (0 to 25) | 1.28 | 66.72. | Pre and midtreatment | -4.38 | <0.017 |
| After 2nd week | 25 (25 to 50) | 1.91 | Mid and posttreatment | -5.01 | <0.017 | ||
| After 4th week | 62.5 (50 to 100) | 2.81 | Pre and posttreatment | -5.49 | <0.017 | ||
| Role limitation due to emotional problem–SF36 | Baseline | 0 (0 to 33.3) | 1.59 | 36.20, | Pre and midtreatment | -2.68 | <0.017 |
| After 2nd week | 33.3 (0 to 66.7) | 1.89 | Mid and posttreatment | -3.72 | <0.017 | ||
| After 4th week | 66.7 (33.3 to 100) | 2.52 | Pre and posttreatment | -4.49 | <0.017 | ||
| Energy/fatigue–SF36 | Baseline | 45 (35 to 50) | 1.18 | 61.82, | Pre and midtreatment | -4.56 | <0.017 |
| After 2nd week | 55 (45 to 60) | 2.03 | Mid and posttreatment | -4.95 | <0.017 | ||
| After 4th week | 60 (50 to 75) | 2.78 | Pre and posttreatment | -5.21 | <0.017 | ||
| Emotional wellbeing–SF36 | Baseline | 52 (44 to 60) | 1.45 | 36.96, | Pre and midtreatment | -3.83 | <0.017 |
| After 2nd week | 56 (52 to 64) | 1.94 | Mid and posttreatment | -4.30 | <0.017 | ||
| After 4th week | 66 (53 to 75) | 2.60 | Pre and posttreatment | -4.61 | <0.017 | ||
| Social functioning–SF36 | Baseline | 43.75 (37.5 to 62.5) | 1.38 | 53.26, | Pre and midtreatment | -3.91 | <0.017 |
| After 2nd week | 62.50 (50 to 75) | 1.89 | Mid and posttreatment | -5.06 | <0.017 | ||
| After 4th week | 75 (62.5 to 87.5) | 2.74 | Pre and posttreatment | -4.95 | <0.017 | ||
| Pain–SF36 | Baseline | 45 (43.1 to 45) | 1.34 | 61.10, | Pre and midtreatment | -4.26 | <0.017 |
| After 2nd week | 55 (45 to 66.87) | 1.92 | Mid and posttreatment | -4.97 | <0.017 | ||
| After 4th week | 67.5 (55 to 86.87) | 2.74 | Pre and posttreatment | -5.17 | <0.017 | ||
| General health–SF36 | Baseline | 40 (35 to 55) | 1.34 | 63.18, | Pre and midtreatment | -3.79 | <0.017 |
| After 2nd week | 52.5 (40 to 65) | 1.76 | Mid and posttreatment | -5.54 | <0.017 | ||
| After 4th week | 75 (50 to 83.75) | 2.90 | Pre and posttreatment | -5.56 | <0.017 |
a Friedman test statistics, b post hoc analysis.
Comparison of craniocervical flexion test and 8 domains of SF 36 within the control group.
| Variable | — | Interquartile range | Mean ranka | Chi-square ( | Post hoc analysis |
|
|
|---|---|---|---|---|---|---|---|
| Craniocervical flexion (mmHg) | Base line | 22 (20 to 24) | 1.18 | 68.70, | Pre and midtreatment | -5.26 | <0.017 |
| After 2nd week | 23 (22 to 26) | 2.09 | Mid and posttreatment | -4.66 | <0.017 | ||
| After 4th week | 24 (24 to 26) | 2.73 | Pre and posttreatment | -5.53 | <0.017 | ||
| Physical functioning–SF36 | Baseline | 40 (21.25 to 55) | 1.41 | 54.25, | Pre and midtreatment | -3.17 | 0.001 |
| After 2nd week | 52.5 (30 to 65) | 1.86 | Mid and posttreatment | -5.03 | <0.017 | ||
| After 4th week | 70 (45 to 80) | 2.73 | Pre and posttreatment | -4.66 | <0.017 | ||
| Role limitation due to physical health–SF36 | Baseline | 0 (0 to 0) | 1.63 | 37.90, | Pre and midtreatment | -2.55 | 0.011 |
| After 2nd week | 0 (0 to 25) | 1.88 | Mid and posttreatment | -4.11 | <0.017 | ||
| After 4th week | 50 (0 to 75) | 2.50 | Pre and posttreatment | -4.45 | <0.017 | ||
| Role limitation due to emotional problem–SF36 | Baseline | 16.65 (0 to 66.70) | 1.88 | 17.03, | Pre and midtreatment | -1.41 | 0.157 |
| After 2nd week | 16.65 (0 to 66.70) | 1.92 | Mid and posttreatment | -2.75 | <0.017 | ||
| After 4th week | 66.70 (0 to 100) | 2.20 | Pre and posttreatment | -2.88 | <0.017 | ||
| Energy/fatigue–SF36 | Baseline | 42.5 (35 to 50) | 1.42 | 48.42, | Pre and midtreatment | -4.01 | <0.017 |
| After 2nd week | 45 (36.25 to 55) | 1.94 | Mid and posttreatment | -4.47 | <0.017 | ||
| After 4th week | 55 (45 to 63.75) | 2.64 | Pre and posttreatment | -4.93 | <0.017 | ||
| Emotional wellbeing–SF36 | Baseline | 52 (40 to 56) | 1.61 | 27.22, | Pre and midtreatment | -2.64 | <0.017 |
| After 2nd week | 52 (40 to 60) | 1.92 | Mid and posttreatment | -4.04 | <0.017 | ||
| After 4th week | 60 (48 to 60) | 2.47 | Pre and posttreatment | -4.13 | <0.017 | ||
| Social functioning–SF36 | Baseline | 50 (37.5 to 62.5) | 1.63 | 35.89, | Pre and midtreatment | -2.44 | 0.015 |
| After 2nd week | 50 (37.5 to 62.5) | 1.85 | Mid and posttreatment | -4.37 | <0.017 | ||
| After 4th week | 62.5 (50 to 75) | 2.52 | Pre and posttreatment | -4.45 | <0.017 | ||
| Pain–SF36 | Baseline | 45 (45 to 45) | 1.45 | 54.60, | Pre and midtreatment | -3.37 | <0.017 |
| After 2nd week | 45 (45 to 67.5) | 1.83 | Mid and posttreatment | -4.45 | <0.017 | ||
| After 4th week | 55 (55 to 77.5) | 2.72 | Pre and posttreatment | -5.13 | <0.017 | ||
| General health perception–SF36 | Base line | 35 (31.25 to 45) | 1.41 | 51.95, | Pre and midtreatment | -3.64 | <0.017 |
| After 2nd week | 40 (35 to 50) | 1.92 | Mid and posttreatment | -4.58 | <0.017 | ||
| After 4th week | 47.5 (40 to 60) | 2.67 | Pre and posttreatment | -5.01 | <0.017 |
Comparison of the baseline craniocervical flexion and 8 domain of SF 36 between the experimental and control group.
| Variable | Group ( | Baseline IQR | Baseline mean ranks | Man Whitney U | Sig. (2-tailed) and effect size (Cohen's |
|---|---|---|---|---|---|
| Craniocervical flexion | Experimental | 21 (20 to 24) | 42.24 | 868.50 |
|
| Control | 22 (20 to 24) | 46.76 | |||
| Physical functioning–SF36 | Experimental | 35 (20 to 55) | 42.82 | 894.0 |
|
| Control | 40 (21.25 to 55) | 46.18 | |||
| Role limitation due to physical health–SF36 | Experimental | 0 (0 to 25) | 46.30 | 889.0 |
|
| Control | 0 (0 to 0) | 42.70 | |||
| Role limitation due to emotional problem–SF36 | Experimental | 0 (0 to 33) | 42.73 | 890.0 |
|
| Control | 16.65 (0 to 66.7) | 46.27 | |||
| Energy/fatigue–SF36 | Experimental | 45 (30.5 to 50) | 44.69 | 959.50 |
|
| Control | 42.5 (35 to 50) | 44.31 | |||
| Emotional wellbeing–SF36 | Experimental | 52 (44 to 60) | 46.73 | 870.0 |
|
| Control | 52 (40 to 56) | 42.27 | |||
| Social functioning–SF36 | Experimental | 43.75 (37.5 to 62.5) | 42.94 | 899.50 |
|
| Control | 50 (37.5 to 62.5) | 46.6 | |||
| Pain–SF36 | Experimental | 45 (43.12 to 45) | 43.24 | 912.50 |
|
| Control | 45 (45 to 45) | 45.76 | |||
| General health perception–SF36 | Experimental | 40 (35 to 55) | 47.76 | 824.50 |
|
| Control | 35 (31.25 to 45) | 41.24 |
Comparison of the craniocervical flexion and 8 domain of SF 36 between the experimental and control group after 2 weeks of treatment.
| Variable | Group ( | After 2nd week IQR | After 2nd week mean ranks | Man Whitney | Sig. (2-tailed) |
|---|---|---|---|---|---|
| Craniocervical flexion | Experimental | 24 (24 to 26) | 50.28 | 713.5 |
|
| Control | 23 (22 to 26) | 38.72 | |||
| Physical functioning–SF36 | Experimental | 57.5 (35 to 70) | 46.6 | 875.50 |
|
| Control | 52.5 (30 to 65) | 42.4 | |||
| Role limitation due to physical health–SF36 | Experimental | 25 (25 to 50) | 53.3 | 581.0 |
|
| Control | 0 (0 to 25) | 35.7 | |||
| Role limitation due to emotional problem–SF36 | Experimental | 33.3 (0 to 66.7) | 46.14 | 896.00 |
|
| Control | 16.65 (0 to 66.7) | 42.86 | |||
| Energy/fatigue–SF36 | Experimental | 55 (45 to 60) | 50.6 | 699.50 |
|
| Control | 45 (36.25 to 55) | 38.4 | |||
| Emotional wellbeing–SF36 | Experimental | 56 (52 to 64) | 52.47 | 617.50 |
|
| Control | 52 (40 to 60) | 36.53 | |||
| Social functioning–SF36 | Experimental | 62.5 (50 to 75) | 50.03 | 724.50 |
|
| Control | 50 (37.5 to 62.5) | 38.97 | |||
| Pain–SF36 | Experimental | 55 (45 to 68.87) | 46.78 | 867.50 |
|
| Control | 45 (45 to 67.5) | 42.22 | |||
| General health perception–SF36 | Experimental | 52.5 (40 to 65) | 52.99 | 594.50 |
|
| Control | 40 (35 to 50) | 36.01 |
Comparison of the craniocervical flexion and 8 domain of SF 36 between the experimental and control group after 4 weeks of treatment.
| Variable | Group ( | After the 4th week IQR | After 4th week mean ranks | Man Whitney | Sig. (2-tailed) |
|---|---|---|---|---|---|
| Craniocervical flexion | Experimental | 26 (24 to 28) | 51.6 | 655.5 |
|
| Control | 24 (24 to 26) | 37.4 | |||
| Physical functioning–SF36 | Experimental | 75 (60 to 85) | 51.3 | 669.0 |
|
| Control | 70 (45 to 80) | 37.70 | |||
| Role limitation due to physical health–SF36 | Experimental | 62.5 (50 to 100) | 51.99 | 638.50 |
|
| Control | 50 (0 to 75) | 37.01 | |||
| Role limitation due to emotional problem–SF36 | Experimental | 66.7 (33.3 to 100) | 50.02 | 725.0 |
|
| Control | 66.7 (0 to 100) | 38.98 | |||
| Energy/fatigue–SF36 | Experimental | 60 (50 to 75) | 51 | 682.0 |
|
| Control | 55 (45 to 63.75) | 38 | |||
| Emotional wellbeing–SF36 | Experimental | 66 (53 to 75) | 52.48 | 617.0 |
|
| Control | 60 (48 to 60) | 36.52 | |||
| Social functioning–SF36 | Experimental | 75 (62.5 to 87.5) | 53.14 | 588.00 |
|
| Control | 62.5 (50 to 75) | 35.86 | |||
| Pain–SF36 | Experimental | 67.5 (55 to 86.87) | 49.43 | 751.00 |
|
| Control | 55 (55 to 77.5) | 39.57 | |||
| General health perception–SF36 | Experimental | 75 (50 to 83.75) | 55.59 | 480.00 |
|
| Control | 47.5 (40 to 60) | 33.41 |